EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
Advanced Science · 2025-08 · 12 (31)
DOI: 10.1002/advs.202506950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 06.06.2025. Verfasst von Yuanzhou Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Lung Neoplasms, Protein Kinase Inhibitors, Dipeptidyl Peptidase 4. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program, National Key Research and Development Program of China.
Abstract (Originalsprache)
Mutations in epidermal growth factor receptor (EGFR) are the key drivers of lung cancer initiation and recurrence. The cancer cells undergo transformation to a reversible drug‐tolerant persister (DTP) state prior to the development of resistance against EGFR‐tyrosine kinase inhibitors (TKIs). Two DTP lung cancer cells with different proliferative capacities are established and identified dipeptidyl peptidase 4 (DPP4) as a potential therapeutic target. The DTP cells primarily relied on oxidative phosphorylation, which is accompanied by the up‐regulation of fatty acid metabolism. Mechanistically, DPP4 facilitates the uptake of fatty acids via carnitine palmitoyl transferase 1a (CPT1A, and enhances fatty acid oxidation. In addition, the DPP4‐mitogen‐activated protein kinase kinase (MEK)‐Nuclear factor erythroid‐2‐related factor 2 (Nrf2) signaling pathway maintains mitochondrial function by activating the antioxidant pathway. The combination of osimertinib and sitagliptin, a DPP4 inhibitor, not only suppressed tumor progression but also reduced the number of residual tumor cells and minimal residual disease. Notably, this combination therapy significantly lowered recurrence rates and extended the survival of tumor‐bearing mice compared to the monotherapies. The study provides new insights into the metabolic adaptations of DTP lung cancer cells in response to EGFR‐TKIs, offering novel therapeutic strategies for targeting these persister cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Liver Surgery and Transplantation, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Xiaoying Luo
Förderung
- National Key Research and Development Program
- National Key Research and Development Program of China
Zitieren
APA
Zhang, Y., Zhang, X., Yang, X., Chen, X., Wang, Y., Hu, J., Liu, R., & Luo, X. (2025). EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer. Advanced Science, 12(31). https://doi.org/10.1002/advs.202506950
Vancouver
Zhang Y, Zhang X, Yang X, Chen X, Wang Y, Hu J, et al. EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer. Advanced Science. 2025;12(31). doi:10.1002/advs.202506950
BibTeX
@article{Zhang2025,
author = {Zhang, Yuanzhou and Zhang, Xiaojun and Yang, Xupeng and Chen, Xingshi and Wang, Yuehong and Hu, Jingying and Liu, Rui and Luo, Xiaoying},
title = {EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {31},
doi = {10.1002/advs.202506950}
}
EUVIMED